



Jun 11, 2021

Access to Source Data/Documents (Part 10 of Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-onset Type 1 Diabetes Mellitus)

In 1 collection

Stephen.Gitelman¹, Jeffrey A. Bluestone²¹Professor of Clinical Pediatrics, Department of Pediatrics University of California, San Francisco Room S-679, Campus Box 0434, 513 Parnassus Avenue, San Francisco, CA 94143;²Professor of Medicine, Pathology, Microbiology & Immunology, University of California, San Francisco, Campus Box 0540, 513 Parnassus Avenue San Francisco, CA 94143

1 Works for me



Share

dx.doi.org/10.17504/protocols.io.bvegn3bw

Gitelman UCSF

Stephen.Gitelman

ABSTRACT

This is Part 10 of "Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus".

This clinical study is supported by JDRF. The aim of the collection is to determine whether imatinib will slow the progression of the autoimmune destruction of β cells and lead to the preservation of C-peptide secretion in T1DM and to assess Diabetes-related objectives and safety of Imatinib in new-onset type 1 diabetes mellitus".

ATTACHMENTS

[dngubkeaf.pdf](#)

DOI

dx.doi.org/10.17504/protocols.io.bvegn3bw

PROTOCOL CITATION

Stephen.Gitelman , Jeffrey A. Bluestone 2021. Access to Source Data/Documents (Part 10 of Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-onset Type 1 Diabetes Mellitus). **protocols.io** <https://dx.doi.org/10.17504/protocols.io.bvegn3bw>

COLLECTIONS ⓘ

**Collection of Protocols and Guidelines for Safety and Efficacy of Imatinib for Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus**

KEYWORDS

Safety, Efficacy, Imatinib, Beta-cell function, New-Onset Type 1 Diabetes Mellitus

LICENSE

This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

May 29, 2021

LAST MODIFIED

Jun 11, 2021

OWNERSHIP HISTORY

May 29, 2021  Urmilas

Jun 03, 2021  Stephen.Gitelman

PROTOCOL INTEGER ID

50344

PARENT PROTOCOLS

Part of collection

[Collection of Protocols and Guidelines for Safety and Efficacy of Imatinib for Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus](#)

GUIDELINES

The investigational sites participating in this study will maintain the highest degree of confidentiality permitted for the clinical and research information obtained from participants in this clinical trial. Medical and research records should be maintained at each site in the strictest confidence. However, as a part of the quality assurance and legal responsibilities of an investigation, the investigational sites must permit authorized representatives of the sponsor, and health authorities to examine (and to copy when required by applicable law) clinical records for the purposes of quality assurance reviews, audits, and evaluation of the study safety and progress. Unless required by the laws permitting copying of records, only the coded identity associated with documents or other participant data may be copied (and any personally identifying information must be obscured). Authorized representatives as noted above are bound to maintain the strict confidentiality of medical and research information that may be linked to identified individuals. The investigational sites will normally be notified in advance of auditing visits.